Regdanvimab Market
The market for Regdanvimab was estimated at $673 million in 2024; it is anticipated to increase to $917 million by 2030, with projections indicating growth to around $1.19 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Regdanvimab Market Outlook
Revenue, 2024
$673M
Forecast, 2034
$1.13B
CAGR, 2025 - 2034
5.3%
The Regdanvimab industry revenue is expected to be around $708.7 million in 2025 and expected to showcase growth with 5.3% CAGR between 2025 and 2034. Building on this steady growth outlook, the Regdanvimab market continues to hold strategic importance within the global infectious disease therapeutics landscape. The therapy gained prominence as healthcare systems sought effective biologic treatments capable of reducing disease progression in high-risk patients. Increasing preparedness for viral outbreaks, strengthening hospital treatment protocols, and continued investment in monoclonal antibody research are reinforcing the relevance of Regdanvimab in modern antiviral therapy strategies. Governments and healthcare providers are also prioritizing stockpiling and rapid response treatment frameworks to improve pandemic preparedness. In addition, collaborations between biotechnology firms, contract manufacturing organizations, and healthcare institutions are supporting production scalability and global distribution capabilities. These developments are helping maintain market relevance while enabling broader integration of monoclonal antibody therapies within infectious disease treatment pathways.
Regdanvimab, also known as Regkirona, is a monoclonal antibody therapy designed to neutralize specific viral pathogens by targeting and binding to proteins responsible for viral entry into human cells. The drug is primarily used in the treatment of mild to moderate viral infections in high-risk patients, particularly in early-stage disease management to prevent progression to severe illness. Administered through intravenous infusion in hospital or clinical settings, Regdanvimab is commonly used in specialized infectious disease units and emergency care facilities. Its targeted mechanism of action enables rapid viral neutralization while supporting the patient’s immune response. Recent trends shaping demand include increasing investments in biologic drug development, expansion of monoclonal antibody platforms, and growing interest in targeted antiviral therapeutics. Pharmaceutical companies are also focusing on improving manufacturing capacity and exploring broader clinical applications, which is expected to strengthen the role of Regdanvimab in future infectious disease management strategies.
Market Key Insights
The Regdanvimab market is projected to grow from $673.0 million in 2024 to $1.13 billion in 2034. This represents a CAGR of 5.3%, reflecting rising demand across COVID-19 Treatment, Prevention of COVID-19, and Research in Airway Diseases.
Celltrion Inc. is the sole producer in this market, holding full control over supply and pricing.
U.S. and UK are the top markets within the Regdanvimab market and are expected to observe the growth CAGR of 3.4% to 5.1% between 2024 and 2030.
Emerging markets including Brazil, Indonesia and South Africa are expected to observe highest growth with CAGR ranging between 6.1% to 7.3%.
Industry players are pushing the adoption of transitions like Transition from emergency pandemic therapeutics to long-term infectious disease biologics development for future years due to existing low growth of 5.3% ; but are also expected to invest $33 million by 2030.
The Regdanvimab market is set to add $455 million between 2024 and 2034, with manufacturer targeting Outpatient Treatment & Emergency Care Application projected to gain a larger market share.
With
increased demand for antiviral drugs, and
Technological Advancements in Biotech Industry, Regdanvimab market to expand 68% between 2024 and 2034.
Opportunities in the Regdanvimab
Strategic collaborations between biotechnology companies, research institutes, and pharmaceutical manufacturers are creating new opportunities for regdanvimab within broader respiratory disease research. Scientists are increasingly exploring monoclonal antibody platforms to develop next-generation biologic treatments for respiratory viruses and airway-related diseases. Through joint research programs and clinical studies, regdanvimab is also being evaluated for its broader immunological and antiviral potential. These collaborations are accelerating innovation in antibody engineering and biologic drug development. Research and experimental therapeutic applications are expected to grow significantly, particularly within academic research institutions and biotechnology laboratories focused on developing advanced respiratory disease treatments.
Growth Opportunities in North America and Asia-Pacific
North America represents a significant regional market for Regdanvimab, supported by advanced healthcare infrastructure, high biopharmaceutical spending, and strong adoption of monoclonal antibody therapies in hospital settings. The United States and Canada are key contributors, with hospitals and infectious disease centers integrating antibody-based antiviral treatments into clinical protocols for high-risk COVID-19 patients. Regional demand is driven by robust healthcare investment and the presence of well-established biopharmaceutical research ecosystems. Top opportunities lie in expanding pandemic preparedness initiatives, government-supported antiviral stockpiling programs, and continued development of next-generation antibody therapies targeting respiratory infections. Competition in the region is moderate but evolving, as alternative COVID-19 antivirals and other monoclonal antibody products influence treatment decisions. Despite this competitive environment, strong regulatory frameworks, clinical research capabilities, and early adoption of biologic therapies continue to sustain demand for regdanvimab across North America’s infectious disease therapeutics market.
Asia-Pacific is projected to be the fastest-growing region for Regdanvimab, driven by expanding healthcare infrastructure, rising investment in biotechnology, and growing awareness of antibody-based therapies. Countries such as South Korea, China, Japan, and India are strengthening pandemic preparedness and infectious disease treatment capabilities, which supports increased adoption of monoclonal antibody therapeutics. The region also benefits from the presence of Celltrion Inc., the developer of regdanvimab, which enhances regional research collaboration and manufacturing capacity. Top opportunities include expanding hospital-based COVID-19 treatment programs, increased government investment in biologic drug development, and growing demand for targeted therapies for immunocompromised patients. Competition is gradually increasing as regional biotechnology companies develop similar antiviral biologics. Nevertheless, large patient populations, improving diagnostic capabilities, and rising healthcare expenditure are expected to drive strong growth for regdanvimab across Asia-Pacific markets.
Market Dynamics and Supply Chain
01
Driver: Growing global preparedness for viral outbreaks and expanding monoclonal antibody research investments
One of the major drivers supporting the regdanvimab market is also the increasing global focus on preparedness for infectious disease outbreaks alongside rising investments in monoclonal antibody research. First, governments and healthcare systems are also strengthening pandemic response strategies following recent global health crises. This includes stockpiling antiviral biologics, expanding hospital treatment protocols, and accelerating regulatory pathways for targeted therapeutics. Such preparedness initiatives are also creating sustained demand for therapies like regdanvimab that can also be rapidly deployed in early-stage viral infections. Second, the biotechnology sector is also investing heavily in monoclonal antibody development platforms. also advances in antibody engineering, cell line development, and large-scale biologic manufacturing are also improving production efficiency and therapeutic performance. These technological advancements are also enabling pharmaceutical companies to develop more effective targeted biologic drugs. Together, these factors are also reinforcing the commercial relevance of regdanvimab and supporting its integration into modern infectious disease treatment frameworks.
Another key driver shaping the regdanvimab market is also the rising adoption of targeted biologic therapies in hospital-based infectious disease management. Healthcare providers are also increasingly prioritizing biologic treatments that directly neutralize viral pathogens rather than relying solely on conventional antiviral drugs. Monoclonal antibody therapies like regdanvimab offer a highly targeted mechanism that can also help reduce disease progression when administered during the early stages of infection. Hospitals and specialized infectious disease units are also integrating these therapies into clinical treatment guidelines, particularly for high-risk patients with weakened immune systems. In addition, advancements in biologics manufacturing and regulatory support for innovative therapeutics are also accelerating the introduction of antibody-based treatments. As healthcare systems continue to adopt precision medicine approaches in infectious disease care, demand for targeted monoclonal antibody therapies such as regdanvimab is also expected to strengthen across global healthcare markets.
02
Restraint: Rapid emergence of immune-evasive SARS-CoV-2 variants reducing monoclonal antibody treatment effectiveness
One of the most significant restraints affecting the regdanvimab market is the rapid emergence of SARS-CoV-2 variants capable of partially evading monoclonal antibody therapies. As viral mutations accumulate in the spike protein targeted by regdanvimab, the drug’s neutralizing capability can decline against certain variants. Clinical research has shown that regdanvimab significantly reduced disease progression in earlier strains but demonstrated limited effectiveness in patients infected with the Delta variant, where outcomes were not significantly different from standard care in some cases. This evolving viral resistance directly impacts market demand because healthcare providers and regulatory bodies may restrict usage when therapeutic performance decreases against dominant circulating strains. As new variants continue to emerge, pharmaceutical companies must frequently update biologic therapies or develop next-generation antibodies, which can slow revenue growth and create uncertainty in long-term commercialization strategies for regdanvimab.
03
Opportunity: Expansion of monoclonal antibody stockpiling programs across government healthcare preparedness initiatives and Growing demand for targeted biologic therapies in high risk patient populations
A key opportunity for the regdanvimab market lies in the expansion of government-led stockpiling programs designed to strengthen preparedness for future viral outbreaks. Many countries are establishing strategic reserves of antiviral therapeutics and monoclonal antibody treatments to ensure rapid response capabilities during emerging infectious disease events. Regdanvimab, administered as an intravenous monoclonal antibody therapy, fits well within these preparedness frameworks because of its targeted viral neutralization capability. Healthcare authorities are increasingly collaborating with biotechnology companies to secure long-term supply agreements. Demand is expected to grow particularly in national public health systems across Asia and the Middle East where pandemic response infrastructure is expanding.
Another opportunity is the rising demand for targeted biologic therapies among high-risk patient groups, including elderly individuals and immunocompromised patients. Hospitals and infectious disease treatment centers are prioritizing therapies that can prevent disease progression in vulnerable populations during viral outbreaks. Regdanvimab offers a targeted therapeutic approach by neutralizing viral activity at early infection stages. This trend is encouraging healthcare providers to adopt monoclonal antibody therapies in specialized clinical protocols for high-risk cases. The mild to moderate viral infection treatment application is expected to expand the most, particularly in advanced healthcare systems where personalized treatment strategies are becoming more common.
04
Challenge: Declining pandemic-driven demand and shifting clinical priorities toward broader antiviral therapies
Another major restraint is the gradual decline in pandemic-driven demand for COVID-19-specific monoclonal antibody treatments as global infection management strategies evolve. During peak pandemic periods, governments and healthcare systems invested heavily in antibody therapeutics for early disease management and hospitalization prevention. However, as vaccination coverage increased and alternative antiviral drugs entered the market, clinical priorities began shifting toward broader and more flexible treatment options. This shift has reduced large-scale procurement programs that previously supported monoclonal antibody sales. In addition, hospitals are increasingly prioritizing treatments with wider variant coverage and easier administration pathways. These changing healthcare strategies influence procurement decisions and reduce consistent demand for regdanvimab, thereby limiting long-term revenue growth and altering competitive dynamics within the antiviral biologics market.
Supply Chain Landscape
1
Biologic API Production
Celltrion Inc.Samsung BiologicsLonza Group
2
Drug Manufacturing
Celltrion Inc.
3
Distribution & Commercialization
Celltrion Healthcare Co. Ltd.DKSH Holding Ltd.Zuellig Pharma
4
Clinical Utilization
COVID-19 TreatmentPrevention of COVID-19Research in Airway Diseases
1
Biologic API Production
Celltrion Inc.Samsung BiologicsLonza Group
2
Drug Manufacturing
Celltrion Inc.
3
Distribution & Commercialization
Celltrion Healthcare Co. Ltd.DKSH Holding Ltd.Zuellig Pharma
4
Clinical Utilization
COVID-19 TreatmentPrevention of COVID-19Research in Airway Diseases
Use Cases of Regdanvimab in COVID-19 Treatment & Prevention of COVID-19
COVID-19 Treatment : COVID-19 Treatment remains the primary application of regdanvimab and accounts for the majority of its clinical utilization across healthcare systems. The therapy is mainly administered as an intravenous monoclonal antibody formulation in hospital settings for patients diagnosed with mild to moderate COVID-19 who are at risk of disease progression. Infectious disease specialists and hospital clinicians use regdanvimab to neutralize viral activity by targeting the spike protein of the SARS-CoV-2 virus, helping reduce viral load during the early stages of infection. This targeted mechanism allows healthcare providers to limit disease severity and reduce hospitalization risks. Specialized COVID-19 treatment centers and tertiary hospitals are the main end users, where controlled infusion protocols and patient monitoring enable effective use of regdanvimab in antiviral therapeutic strategies.
Prevention of COVID-19 : Prevention of COVID-19 has emerged as another important application of regdanvimab, particularly for high-risk populations who may not respond adequately to vaccines or who require additional protection during outbreaks. In this preventive setting, the intravenous monoclonal antibody formulation is used in clinical environments such as hospitals, specialty clinics, and infectious disease treatment units. Healthcare providers administer regdanvimab to individuals with compromised immune systems or chronic health conditions who are more vulnerable to severe infection. The therapy works by providing passive immunity that helps block viral entry into human cells. This approach supports broader public health strategies aimed at reducing infection spread among vulnerable groups, making regdanvimab a valuable component of preventive treatment programs in specialized healthcare settings.
Research in Airway Diseases : Research in Airway Diseases represents an emerging application where regdanvimab is being studied within biomedical and respiratory research programs. Research institutions and biotechnology laboratories are exploring the therapeutic potential of monoclonal antibody platforms for various respiratory and airway related conditions. In this context, the same intravenous biologic formulation of regdanvimab is primarily used in experimental and preclinical studies to understand immune responses and viral neutralization mechanisms within respiratory pathways. Scientists are investigating how monoclonal antibodies interact with airway tissues and viral pathogens to support the development of next generation respiratory therapeutics. This research activity is contributing to broader advancements in biologic drug development and expanding interest in antibody based treatments for complex respiratory diseases.
Impact of Industry Transitions on the Regdanvimab Market
As a core segment of the Pharmaceutical industry,
the Regdanvimab market develops in line with broader industry shifts.
Over recent years, transitions such as Transition from emergency pandemic therapeutics to long-term infectious disease biologics development and Integration of monoclonal antibody therapeutics with precision infectious disease treatment models have redefined priorities
across the Pharmaceutical sector,
influencing how the Regdanvimab market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Transition from emergency pandemic therapeutics to long-term infectious disease biologics development
The regdanvimab industry is transitioning from pandemic-driven emergency use toward a broader infectious disease biologics development framework. During the peak of COVID-19, monoclonal antibody therapies were rapidly deployed to reduce hospitalization risks. As global healthcare systems move beyond emergency response, pharmaceutical companies are repositioning such biologics within long-term antiviral research pipelines. This transition is influencing biotechnology and pharmaceutical industries by encouraging continued investment in antibody discovery platforms and biologic drug manufacturing capabilities. Contract development and manufacturing organizations are also expanding large-scale biologics production facilities to support future antiviral therapies and pandemic preparedness programs.
02
Integration of monoclonal antibody therapeutics with precision infectious disease treatment models
Another important industry transition involves the integration of monoclonal antibody therapies like regdanvimab into precision infectious disease treatment models. Healthcare providers are increasingly adopting targeted therapies tailored to specific pathogens and patient risk profiles rather than relying solely on broad antiviral medications. This shift is impacting multiple sectors including molecular diagnostics, hospital treatment protocols, and biotechnology research. Diagnostic companies are developing rapid pathogen identification tools that help clinicians select targeted biologic treatments. At the same time, pharmaceutical companies are collaborating with research institutions to develop next-generation antibody therapies, strengthening the ecosystem connecting diagnostics, biologics development, and personalized infectious disease care.